×
Kura Oncology Total Assets 2012-2024 | KURA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Kura Oncology total assets from 2012 to 2024. Total assets can be defined as the sum of all assets on a company's balance sheet.
View More
Kura Oncology Total Assets 2012-2024 | KURA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Kura Oncology total assets from 2012 to 2024. Total assets can be defined as the sum of all assets on a company's balance sheet.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$160.6B
Vertex Pharmaceuticals (VRTX)
$126.2B
Bristol Myers Squibb (BMY)
$119.7B
Gilead Sciences (GILD)
$117.5B
Regeneron Pharmaceuticals (REGN)
$90.2B
CSL (CSLLY)
$90B
GSK (GSK)
$73.6B
Argenex SE (ARGX)
$35.5B
Alnylam Pharmaceuticals (ALNY)
$34.7B
BioNTech SE (BNTX)
$25.5B
Biogen (BIIB)
$24.5B
Illumina (ILMN)
$23.4B
BeiGene (BGNE)
$18.9B
Moderna (MRNA)
$16.7B
Incyte (INCY)
$15.5B
Genmab (GMAB)
$14.9B
BioMarin Pharmaceutical (BMRN)
$12.6B
Insmed (INSM)
$12.5B
Vaxcyte (PCVX)
$12.4B
Bio-Techne Corp (TECH)
$11.8B
Sarepta Therapeutics (SRPT)
$10.9B
Exelixis (EXEL)
$10.2B
Revolution Medicines (RVMD)
$10B
QIAGEN (QGEN)
$9.9B
Intra-Cellular Therapies (ITCI)
$9.4B
Bio-Rad Laboratories (BIO.B)
$9.4B
Exact Sciences (EXAS)
$9.3B
Roivant Sciences (ROIV)
$8.6B
Repligen (RGEN)
$8.3B
Ascendis Pharma (ASND)
$7.7B